TRAVERSE didn’t say what your clinic claims 🧬

LONGEVITY LATEST | Issue 11 | 13 May 2026

LONGEVITY LATEST

The Evidence-Based Edge on Living Longer and Better

THIS WEEK

👋 Welcome

More fractures, not fewer. That’s what 5,200 men on testosterone produced after three years in the cleanest trial we have. If you’ve ever been offered hormone therapy as anti-ageing — or know someone weighing it — that result is the part of the conversation your clinic hasn’t reached yet.

This week audits hormone optimisation from both ends: the TRT contradiction in older men, and the regulatory correction in early-menopause women that the FDA quietly issued last November.

In November 2025 the FDA changed the menopausal HRT label to acknowledge what twenty years of re-analysis had been saying — initiated within ten years of menopause, the cardiovascular profile of hormone therapy is neutral to favourable. The first regulatory correction in this space since 2002.

Inside:

• 🔬 Top 3: TRT in hypogonadism, transdermal estradiol + micronised progesterone, enclomiphene

• ⭐ Spotlight: HRT — the twenty-three-year correction

• 🚨 Hype Check: £600 pellet clinics and the "bioidentical optimisation" pitch

• 🥦 Superfood: Cruciferous vegetables — the I3C/DIM pathway

• 📖 Deep Dive: The bone surrogate forty years of endocrinology got wrong

• 🏋 Biohacking Corner: Earn the numbers before you replace them

TOP 3

🔬 Top 3 Interventions Under the Microscope

1.

Testosterone Replacement (Symptomatic Hypogonadism) — Evidence Grade: B

What it is. Replacement-dose testosterone — gel, weekly injection, or transdermal — restoring serum total testosterone into the mid-normal range (15–25 nmol/L) in men with biochemically confirmed hypogonadism plus symptoms. Licensed product, prescribed correctly, in men whose pituitary–gonadal axis is failing. Not a wellness product.

Human evidence. TRAVERSE (Lincoff et al., NEJM 2023, n=5,246, 33-month median follow-up) is the trial the field had been waiting fifteen years for. Men 45–80, hypogonadism plus high cardiovascular risk, randomised to topical testosterone or placebo. The headline cardiac endpoint — heart attack, stroke, cardiac death — came in non-inferior. That ended a long argument.

Same trial, same population, two findings that reset the conversation. Clotting events ran 46% higher in the testosterone arm. And the Fracture sub-study (Snyder et al., NEJM 2024) found 3.5% of treated men suffered a clinical fracture versus 2.5% on placebo — wrong direction for a hormone we’ve been telling patients builds bone.

Read the paper, not the press release. Testosterone for symptomatic, biochemically defined hypogonadism has 5,000-man trial support on the cardiac question. As a generic ageing-optimisation tool, it doesn’t.

Cautions. Clotting risk meaningfully elevated — flag personal or family history. Rising red-cell count (polycythaemia) needs quarterly bloods in the first year. Shuts down the body’s own testosterone signalling — sperm counts drop in roughly half of treated men. Lowers HDL. Can mask the symptoms of an underlying mood or sleep disorder that was the real culprit.

Takeaway. Replacement in confirmed hypogonadism — backed by the largest RCT we have, with two safety asterisks. Evidence Grade B. Outside that indication, the data does not exist. Most men buying TRT in 2026 are not the men who were enrolled in TRAVERSE.

2.

Transdermal Estradiol + Micronised Progesterone (Early-Menopause HRT) — Evidence Grade: A

What it is. Estradiol delivered through a patch, gel, or spray — bypassing first-pass hepatic metabolism — paired with oral micronised progesterone in women with an intact uterus. Mundane in clinical-pharmacology terms. Quietly transformational in the oncology and cardiovascular columns.

Human evidence. Two interlocking literatures the WHI generation got wrong. First, the route. A 2024 pooled meta-analysis of comparative oral-versus-transdermal trials puts the clotting relative-risk point estimates at 1.48–1.9 for oral preparations and 0.97–1.0 for transdermal — the skin route is statistically indistinguishable from no hormone at all on clotting. Mechanism: oral estrogen passes through the liver, induces thrombin generation, and creates resistance to activated protein C. Transdermal doesn’t.

Personal note: I’ve watched smart cardiologists assume the two routes are interchangeable on this. They aren’t. The hepatic pass is the whole game.

Second, the progestin. Micronised progesterone — bioidentical — does not increase breast cancer risk in pooled cohort and RCT data (Asi 2016; Yuk IJGO 2024 nationwide cohort, RR vs synthetic progestins 0.67, 95% CI 0.55–0.81). Medroxyprogesterone acetate, the synthetic compound used in the 2002 WHI arm that frightened a generation off hormone therapy, does. And in November 2025 the FDA updated its menopausal HRT label to acknowledge the timing hypothesis: initiated within ten years of menopause or before age sixty, the cardiovascular profile is neutral to favourable.

Translation. If you’re a symptomatic woman within the timing window, the modern transdermal-plus-micronised-progesterone protocol is not the treatment that frightened your mother in 2002. Different molecule, different route, twenty years of corrective evidence.

Cautions. Hormone-sensitive cancer (active or prior) is a contraindication. Same for active clotting events, severe liver disease, undiagnosed vaginal bleeding. Migraine with aura — transdermal by default. Past sixty, or more than ten years post-menopause, the timing-hypothesis evidence stops carrying you.

Takeaway. Route, molecule, and timing window each move the needle independently — the evidence base now defends each call separately. Evidence Grade A — within the window, on the right molecules, by the right route. Outside that window, downgrade.

3.

Enclomiphene — Evidence Grade: C

What it is. A SERM that blocks oestrogen’s negative feedback at the pituitary, raising endogenous LH and FSH, which raises testosterone without shutting down sperm production. Marketed as "TRT without the trade-offs." Half-true.

Human evidence. Two Phase III trials (ZA-304 and ZA-305, Wiehle et al., BJU International 2014, n>250 combined) pitted enclomiphene against transdermal testosterone in overweight men with secondary hypogonadism. Both raised total testosterone into the normal range. The differentiator was sperm. More than half of TRT-treated men became oligospermic; about 15% of enclomiphene men did. That’s a real clinical advantage for a man wanting symptomatic relief without losing fertility.

So why a C, not a B. The FDA has refused this drug twice. A 2015 Complete Response Letter cited inadequate trial design, and the manufacturer shelved development in 2021. Every gram of enclomiphene prescribed in the UK or US is compounded — unlicensed, variable-purity, riding on those two trials and a thin envelope of off-label experience.

Cautions. Off-label and unlicensed in the UK and US. Mood effects — irritability, depressive symptoms — show up post-market more often than the trials predicted. Safety past 12 months is thin.

Takeaway. A clever option for a narrow indication, riding Phase III evidence the regulators didn’t accept. Evidence Grade C. If the goal is preserving fertility while treating secondary hypogonadism, the rational choice — under specialist supervision. Otherwise, licensed alternatives carry more data.

SPOTLIGHT

⭐ Spotlight: HRT — The Twenty-Three-Year Correction

This one isn’t an evidence audit — the evidence sits in Top 3 #2 above. This is the clinical-history audit: how a single 2002 press conference cost a generation of women a treatment the trial wasn’t actually testing the way the headlines said.

On 9 July 2002 the NIH halted the WHI estrogen-plus-progestin arm early and convened a press briefing. The morning news headline: hormone therapy "increased breast cancer and heart disease." What the briefing did not foreground: average enrolment age was 63, two-thirds of participants were over a decade past menopause, the progestin was medroxyprogesterone acetate — not bioidentical — and the route was oral conjugated equine estrogen, not transdermal.

What twenty years of re-analysis has shown

• Age-stratified re-analyses are broadly consistent — initiated within ten years of menopause, the cardiovascular column flips from net harm to neutral or favourable.

• The route and progestin distinctions Top 3 #2 unpacks have been replicated across cohorts.

• The FDA’s November 2025 label change codifies the timing hypothesis as a binding label, not editorial opinion.

What hasn’t been corrected

• Twenty-three years of underprescribing has produced a cohort of women in their seventies whom the timing hypothesis can no longer help.

• Clinician familiarity varies wildly. A woman at 51 in 2026 gets materially different advice depending on which GP she sees.

• "HRT causes cancer" remains a sticky belief among women who were teenagers in 2002.

Three things were wrong with the 2002 headline — the age, the route, and the progestin. The trial was never actually testing what the morning bulletin said it was testing.

HYPE CHECK

🚨 Hype Check: £600 Testosterone-Pellet "Optimisation" Clinics

SUPERFOOD

🥦 Superfood Spotlight: Cruciferous Vegetables

DEEP DIVE

📖 Deep Dive — The Bone Surrogate Forty Years of Endocrinology Got Wrong

The Snyder team had to report a finding their trial wasn’t designed to investigate. So in the discussion section they floated a hypothesis they would have preferred not to: that the bone measurement endocrinology has been using to tell men "your skeleton is improving on testosterone" is the wrong measurement.

That has implications beyond the 5,200 men in TRAVERSE. The companion piece walks the candidate mechanism, the 2017 imaging study Snyder cites as precedent, and the question every man on TRT now has to ask his prescriber.

👉 Read: When More Testosterone Made Bones Weaker — and the Question Every Man Now Has to Ask

BIOHACKING

🏋 Biohacking Corner: Earn the Numbers Before You Replace Them

Half the men I know on TRT in their forties got there because they stopped sleeping, stopped lifting, gained twelve kilos, and had the bloods done a year too late. The other half had genuine primary hypogonadism. Only one group belongs on a script. The audit goes like this.

1. Sleep is the cheapest hormone-optimisation tool ever built. Total testosterone drops 10–15% after a single week of five-hour nights (van Cauter et al., JAMA 2011). Fix sleep first. Eight hours, dark room, alcohol off after Tuesday.

2. Carry less visceral fat. Aromatase — the enzyme that converts testosterone to oestradiol — lives in adipose tissue. A man at 30% body fat aromatises a meaningful fraction of his own production into oestrogen. Fat loss isn’t cosmetic here.

3. Lift heavy, twice a week minimum. Resistance training acutely raises testosterone and chronically raises androgen-receptor density. The second is what matters for symptoms. Compound lifts: deadlift, squat, press, row.

4. Fix the boring deficiencies. Zinc, magnesium, vitamin D. None of these are testosterone supplements. All three, when actually deficient, suppress endogenous testosterone production. Most men are deficient in at least one.

5. Get a second blood test before any clinic puts you on a script. Testosterone varies 20–30% week-to-week. Single-shot bloods convert curious men into customers.

READER PULSE

📊 Reader Pulse

Last week’s poll — "How often do you use a sauna?" — drew the most evenly distributed response of any LL poll so far. The "occasionally — at a hotel or gym" tribe led at a third. The 4+ a week Finnish-cohort tribe came in at 12%. "Never — no access" was bigger than I’d expected at one in five. Editorial take: the access constraint is real. Issue 10’s Biohacking Corner was written for the 4+ tribe; the infrared-at-the-gym pivot probably matters more for most readers than I gave it credit for.

🎯 Closing

Issue 12 takes apart the Bryan Johnson stack — line by line, with evidence grades for each of the 70-plus pills. Plus: when a £4 multivitamin beats a £400 personalised stack, and a Hype Check on at-home epigenetic age tests now that GrimAge has gone consumer.

Stay curious and stay healthy!

— Christian Thomsen, Editor

Longevity Latest is published weekly by FrontWave Media Ltd. The content is for educational purposes and does not constitute medical advice. Hormone therapy of any kind should be initiated and supervised by a qualified clinician with full bloods, history, and follow-up. Consult your physician before starting, stopping, or changing any hormone, supplement, or medication, particularly if you are pregnant, nursing, managing a chronic condition, or on prescription medication.